The clinical interpretation of viral blips in HIV patients receiving antiviral treatment: Are we ready to infer poor adherence?

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 1, 2012, Pages 5-11

  Fung, Isaac C H ^a   Gambhir, Manoj ^a   Van Sighem, Ard ^a,b   De Wolf, Frank ^a,b   Garnett, Geoffrey P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Drug adherence; HIV; Mathematical modeling; Sampling frame; Viral blips

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; SAMPLING; SENSITIVITY ANALYSIS; VIRAL BLIP;

ANTI-HIV AGENTS; DRUG MONITORING; HIV; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MODELS, THEORETICAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 84862119629     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182487a20     Document Type: Article

References (29)

1. Stosor V, Palella FJ Jr, Berzins B, et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis. 2005;41:1671-1674. (Pubitemid 41691608)
2. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293: 817-829. (Pubitemid 40250365)
3. Jones LE, Perelson AS. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol. 2005;67:1227-1251. (Pubitemid 41323803)
4. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-Infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;45:483-493. (Pubitemid 47294919)
5. Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol. 2009;5:e1000533.
6. Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to, 400 copies/ml. AIDS. 2002;16:1521-1527. (Pubitemid 34804217)
7. Masquelier B, Pereira E, Peytavin G, et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol. 2005;33:75-78. (Pubitemid 40431581)
8. Podsadecki TJ, Vrijens BC, Tousset EP, et al. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2007;196:1773-1778. (Pubitemid 351411937)
9. Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28:105-113. (Pubitemid 32971057)
10. Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51:195-200. (Pubitemid 41554826)
11. Rong L, Perelson AS. Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol. 2009;260:308-331.
12. Fung IC-H, Gambhir M, van Sighem A, et al. Superinfection with a heterologous HIV strain per se does not lead to faster progression. Math Biosci. 2010;224:1-9.
13. Garcia-Gasco P, Maida I, Blanco F, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61:699-704. (Pubitemid 351324637)
14. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967-1969.
15. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286: 171-179. (Pubitemid 32640848)
16. Martinez V, Marcelin AG, Morini JP, et al. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2005;19:1065-1069. (Pubitemid 40961147)
17. Miller LG, Golin CE, Liu HH, et al. No evidence of an association between transient HIV viremia ("blips") and lower adherence to the antiretroviral medication regimen. J Infect Dis. 2004;189:1487-1496. (Pubitemid 38543599)
18. Mira JA, Macias J, Nogales C, et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther. 2002;7: 251-256. (Pubitemid 36427129)
19. Moore AL, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS. 2002;16:615-618. (Pubitemid 34218857)
20. Raboud JM, Rae S, Woods R, et al. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS. 2002;16:1627-1632. (Pubitemid 34921108)
21. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS. 2002;16:2035-2041. (Pubitemid 35205267)
22. Sungkanuparph S, Overton ET, Seyfried W, et al. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis. 2005;41:1326-1332. (Pubitemid 41532678)
23. van Sighem A, Zhang S, Reiss P, et al. Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2008; 48:104-108. (Pubitemid 351600855)
24. Di Mascio M, Percus JK, Percus OE, et al. Duration of an intermittent episode of viremia. Bull Math Biol. 2005;67:885-900. (Pubitemid 40707617)
25. Ferguson NM, Donnelly CA, Hooper J, et al. Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface. 2005;2:349-363.
26. Percus JK, Percus OE, Markowitz M, et al. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol. 2003;65:263-277. (Pubitemid 36333243)
27. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol. 2003;77:12165-12172. (Pubitemid 37339869)
28. Di Mascio M, Ribeiro RM, Markowitz M, et al. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci. 2004;188:47-62. (Pubitemid 38177304)
29. Rong L, Perelson AS. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci. 2009;217:77-87.